Compreendendo as relações entre MRD e terapia com células T CAR
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
Terapia com células-tronco mesenquimais em distúrbios neurológicos
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
A designação de medicamento órfão é dada pela FDA ao CART T-Cell Therapy A2B530 para o tratamento do câncer colorretal
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Amtagvi da Iovance é aprovado pela USFDA como primeira terapia com células T para um tumor sólido
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
Amivantamab-vmjw é aprovado pelo USFDA para indicações de câncer de pulmão de células não pequenas com mutação de inserção do exon 20 do EGFR
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
Osimertinibe com quimioterapia é aprovado pela USFDA para câncer de pulmão de células não pequenas com mutação de EGFR
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Lifileucel é aprovado pela USFDA para melanoma irressecável ou metastático
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
Tepotinibe é aprovado pela USFDA para câncer de pulmão metastático de células não pequenas
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
Lipossomo de irinotecano é aprovado pela USFDA para tratamento de primeira linha de adenocarcinoma pancreático metastático
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
Erdafitinibe é aprovado pela USFDA para carcinoma urotelial localmente avançado ou metastático
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..